| Quarter | Score |
|---|---|
| 2022-Q1 | 50.1 |
| 2022-Q3 | 66.7 |
| 2022-Q4 | 49.7 |
| 2023-Q1 | 49.2 |
| 2023-Q2 | 63.9 |
| 2023-Q3 | 48.1 |
| 2023-Q4 | 36.0 |
| 2024-Q1 | 47.3 |
| 2024-Q2 | 45.9 |
| 2024-Q3 | 78.7 |
| 2024-Q4 | 75.8 |
| 2025-Q1 | 76.9 |
| 2025-Q2 | 76.7 |
| 2025-Q3 | 75.6 |
| 2025-Q4 | 76.0 |
| 2026-Q1 | 76.1 |
| 2026-Q2 | 76.2 |
Funds reducing exposure or consensus momentum fading
Trading +50.3% above funds' purchase price — elevated pullback risk
2 of 18 tracked funds hold FCX. Avg conviction: 0.5%. Net trimming. First tracked at $48.47 (current +50.3% vs tracked).
Oaktree Capital has 1.0% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Oaktree Capital | 1.0% | Reduce |
| Citadel Advisors | 0.0% | Reduce |